Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Evolus Inc
(NQ:
EOLS
)
11.40
-0.18 (-1.55%)
Streaming Delayed Price
Updated: 11:11 AM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Evolus Inc
< Previous
1
2
3
Next >
Evolus to Report Third Quarter 2022 Results and Provide Business Update
October 25, 2022
From
Evolus
Via
Business Wire
Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain
October 04, 2022
From
Evolus
Via
Business Wire
Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022
September 21, 2022
From
Evolus
Via
Business Wire
Evolus Announces Inducement Grants for New Chief Financial Officer
September 06, 2022
From
Evolus
Via
Business Wire
Evolus Appoints Sandra Beaver as Chief Financial Officer
August 30, 2022
From
Evolus
Via
Business Wire
Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 29, 2022
From
Evolus
Via
Business Wire
Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®
August 24, 2022
From
Evolus
Via
Business Wire
Evolus Reports Second Quarter 2022 Results and Provides Business Update
August 02, 2022
From
Evolus
Via
Business Wire
Evolus to Report Second Quarter 2022 Results and Provide Business Update
July 19, 2022
From
Evolus
Via
Business Wire
Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”
July 19, 2022
From
Evolus
Via
Business Wire
Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
July 12, 2022
From
Evolus
Via
Business Wire
Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed
June 02, 2022
From
Evolus
Via
Business Wire
Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States
May 18, 2022
From
Evolus
Via
Business Wire
Evolus to Participate in the H.C. Wainwright Global Investment Conference
May 11, 2022
From
Evolus
Via
Business Wire
Evolus Reports First Quarter 2022 Results and Provides Business Update
May 10, 2022
From
Evolus
Via
Business Wire
Evolus to Report First Quarter 2022 Results and Provide Business Update
April 26, 2022
From
Evolus
Via
Business Wire
Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
March 31, 2022
From
Evolus
Via
Business Wire
EVOLUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Evolus, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 29, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Evolus to Report Fourth Quarter and Year End 2021 Results and Provide Business Update
February 17, 2022
From
Evolus
Via
Business Wire
Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva®
February 08, 2022
From
Evolus
Via
Business Wire
Evolus to Participate in the Virtual 11th Annual SVB Leerink Global Healthcare Conference
February 02, 2022
From
Evolus, Inc.
Via
Business Wire
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance
January 26, 2022
From
Evolus, Inc.
Via
Business Wire
Evolus Expands Board of Directors With Appointment of Digital and Beauty Innovator Brady Stewart
January 05, 2022
From
Evolus
Via
Business Wire
Evolus Joins Nasdaq Biotechnology Index
December 20, 2021
From
Evolus
Via
Business Wire
Evolus Enters Into $125 Million Credit Facility with Pharmakon Advisors
December 14, 2021
From
Evolus, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.